Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Metadata
Title
p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study
Authors
Kazuharu Kai
Reiki Nishimura
Nobuyuki Arima
Haruhiko Miyayama
Hirotaka Iwase
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 6/2006
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-006-0601-6

Other articles of this Issue 6/2006

International Journal of Clinical Oncology 6/2006 Go to the issue

ORIGINAL ARTICLE

Inflammatory pseudotumor of the lung: clinicopathological analysis in seven adult patients

ORIGINAL ARTICLE

In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues

ORIGINAL ARTICLE

Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation

CASE REPORT

The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient

ORIGINAL ARTICLE

“Watch-and-see” policy for the clinically positive neck in head and neck cancer treated with chemoradiotherapy

CASE REPORT

Resistance to gefitinib
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits